ArticleJournal of translational autoimmunity2022
Antinuclear antibodies (ANA) as a criterion for classification and diagnosis of systemic autoimmune diseases.
Article in Journal of translational autoimmunity, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 47 citations in OpenAlex.
- Antinuclear antibody titre and its dynamics predict autoimmune disease progression in adults with immune thrombocytopenia.Clinical rheumatology · 2026Article
- Association of isolated anti-Scl-70 positivity with subclinical cardiac involvement in ANA-positive individuals: an electrocardiographic diastolic function analysis (Subclinical Cardiac Involvement in Isolated Anti-Scl-70 Positivity).Immunologic research · 2026Article
- Decoding Lupus Diagnosis, Pathogenesis and Therapy: From Systemic Autoimmunity to Renal Damage.Diagnostics (Basel, Switzerland) · 2026Review
- Anti-Cell Staining Patterns in Juvenile Idiopathic Arthritis-Associated Uveitis: A Peek Behind the Curtain.Journal of clinical medicine · 2026Article
- Rethinking biomarker strategy in gastric cancer immunotherapy: from tumor to host.Frontiers in immunology · 2026Review
- VII Brazilian Consensus guidelines for the detection and interpretation of anti-cell autoantibodies on HEp-2 cells.Advances in rheumatology (London, England) · 2025Review
- Predictive Value of Laboratory Assays Toward Autoimmune Diseases.Journal of clinical laboratory analysis · 2025Article
- Pilot Study of AI-Assisted ANA Immunofluorescence Reading-Comparison with Classical Visual Interpretation.Journal of clinical medicine · 2025Article
- Anti-Nuclear Antibody Staining Patterns in Juvenile Idiopathic Arthritis: Association of AC-1 Pattern and Elevated Titers with Uveitis.Medeniyet medical journal · 2025Article
- Mapping of the Antinuclear Autoantibodies in Sudanese patients infected with Human Immunodeficiency Virus after HAART receiving: A cross-sectional study.Scientific reports · 2025Article
- CytoBead ANA 2 assay - a novel method for the detection of antinuclear antibodies.Scientific reports · 2025Article
- Effect of Age on Xenobiotic-Induced Autoimmunity.bioRxiv : the preprint server for biology · 2025Article
- Dietary Fatty Acids and Antinuclear Antibodies Among Adults with Arthritis in the United States: NHANES 1999-2004.Nutrients · 2025Article
- Evaluation of ILAR and PRINTO classifications for juvenile idiopathic arthritis: oligoarticular JIA vs early-onset ANA-positive JIA.Clinical rheumatology · 2025Article
- Mortality in Antinuclear Antibody-Positive Patients with and Without Rheumatologic Immune-Related Disorders: A Large-Scale Population-Based Study.Medicina (Kaunas, Lithuania) · 2025Article
- Epidemiological Analysis of Antinuclear Antibodies Positivity and Pattern Distribution in a Taiwanese Hospital-Based Cohort.British journal of biomedical science · 2025Article
- Referrals for rheumatologic evaluation following a positive antinuclear antibody test result. A cross-sectional single center Brazilian study.Advances in rheumatology (London, England) · 2024Article
- The STING inhibitor (ISD-017) reduces glomerulonephritis in 129.B6.Fcgr2b-deficient mice.Scientific reports · 2024Article
- Comprehensive Exploration of Antinuclear Antibodies (ANAs): Unveiling Clinical Significance, Associations with Cancer, and the Nuances of Differential Diagnosis in Positive ANA Patients.Diagnostics (Basel, Switzerland) · 2024Review
- Discriminating between Homogeneous (AC-1) and Dense Fine Speckled (AC-2) Antinuclear Antibody Patterns: Re-Evaluation of Immunofluorescence Imaging.Biomedicines · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The classification and diagnosis of systemic autoimmune diseases are frequently based on a collection of criteria composed of clinical, laboratory, imaging, and pathology elements that are strongly associated with the respective disease. Autoantibodies are a distinctive hallmark and have a prominent position in the classification criteria of many autoimmune diseases. The indirect immunofluorescence assay on HEp-2 cells (HEp-2 IFA), historically known as the antinuclear antibody test, is a method capable of detecting a wide spectrum of autoantibodies. A positive HEp-2 IFA test is part of the classification criteria for systemic lupus erythematosus (SLE) and juvenile idiopathic arthritis (JIA), as well as the diagnostic criteria for autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC). A positive HEp-2 IFA test can appear as different morphological patterns that are indicative of the most probable autoantibody specificities in the sample. Only some of the HEp-2 IFA patterns are associated with the specific autoantibodies relevant to SLE, JIA, AIH, and PBC, whereas some other patterns occur mainly in non-related conditions and even in apparently healthy individuals. This paper provides a critical review on the subject and proposes that the classification and diagnostic criteria for SLE, JIA, AIH, and PBC could be improved by a modification on the HEp-2 IFA (ANA) criterion in that the staining patterns accepted for each of these diseases should be restricted according to the respective relevant autoantibody specificities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.